Citations

Clear

4847 citation(s) found for "Tu, Eric".

Magnetic resonance elastography (MRE) of the human brain: technique, findings and clinical applications
Hiscox, Lucy V. , McGarry, Matt D J, Starr, John M. , Roberts, Neil , Johnson, Curtis L. , Barnhill, Eric , McGarry, Matthew D. J. , Huston, John , Beek, Edwin J.R. van

Mayo Clinic

Physics in Medicine & Biology | November 15, 2016 | Volume: 61 | Issue: 24 | Pages: R401-R437

10.1088/0031-9155/61/24/r401 | PMID 27845941 Get It

Abstract Neurological disorders are one of the most important public health concerns in developed countries. Established brain imaging techniques such as magnetic resonance imaging (MRI) and x-ray computerised tomography (CT) have been essential in the identification and diagnosis of a wide range of disorders, although usually are insufficient in sensitivity for detecting subtle pathological alterations to the brain prior to the onset of clinical symptoms—at a time when prognosis for treatment is more favourable. The mechanical properties of biological tissue provide information related to the strength and integrity of the cellular microstructure. In recent years, mechanical properties of the brain have been visualised and measured non-invasively with magnetic resonance elastography (MRE), a particularly sensitive medical imaging technique that may increase the potential for early diagnosis. This review begins with an introduction to the various methods used for the acquisition and analysis of MRE data. A systematic literature search is then conducted to identify studies that have specifically utilised MRE to investigate the human brain. Through the conversion of MRE-derived measurements to shear stiffness (kPa) and, where possible, the loss tangent (rad), a summary of results for global brain tissue and grey and white matter across studies is provided for healthy participants, as potential baseline values to be used in future clinical investigations. In addition, the extent to which MRE has revealed significant alterations to the brain in patients with neurological disorders is assessed and discussed in terms of known pathophysiology. The review concludes by predicting the trends for future MRE research and applications in neuroscience.
Survey of Current Practices from the International Stereotactic Body Radiotherapy Consortium (Isbrtc) for Head and Neck Cancers
Karam, Irene , Yao, Min , Heron, Dwight E. , Poon, Ian , Koyfman, Shlomo A. , Yom, Sue S. , Siddiqui, Farzan , Lartigau, Éric, Cengiz, Mustafa , Yamazaki, Hideya , Hara, Wendy, Phan, Jack , Vargo, John A. , Lee, Victor , Foote, Robert L. , Harter, K. William, Lee, Nancy Y. , Sahgal, Arjun , Lo, Simon S. , Yom, Sue S , Phan, Jack

Mayo Clinic

Future Oncology | November 15, 2016 | Volume: 13 | Issue: 7 | Pages: 603-613

10.2217/fon-2016-0403 | PMID 27842456 Get It

Response by Herrmann et al to Letter Regarding Article, “Vascular Toxicities of Cancer Therapies: The Old and the New—An Evolving Avenue”
Herrmann, Joerg , Yang, Eric H. , Iliescu, Cezar , Marmagkiolis, Konstantinos , Yang, Eric

Mayo Clinic

Circulation | November 14, 2016 | Volume: 134 | Issue: 20 | Pages: No page available

10.1161/circulationaha.116.024415 | PMID 27881502 Get It

Progressive Decline of Lung Function in Rheumatoid Arthritis–Associated Interstitial Lung Disease
Zamora‐Legoff, Jorge A. , Krause, Megan L., Crowson, Cynthia S. , Ryu, Jay H. , Matteson, Eric L. , Ryu, Jay H

Mayo Clinic

Arthritis & Rheumatology | November 10, 2016 | Volume: 69 | Issue: 3 | Pages: 542-549

10.1002/art.39971 | PMID 27788297 Get It

ObjectiveInterstitial lung disease (ILD) is associated with substantial morbidity in rheumatoid arthritis (RA), but very little is known about its long‐term progression. This study was undertaken to investigate the progression of pulmonary disease using a large single‐center cohort of patients with RA‐associated ILD.MethodsRecords of all patients with RA‐associated ILD seen at Mayo Clinic between 1998 and 2014, with at least 4 weeks follow‐up and at least 1 pulmonary function test, were identified and manually screened for study inclusion. Progression was defined as a diffusing capacity for carbon monoxide (DLco) <40% predicted (or patients whose illness was too advanced to undergo screening) or a forced vital capacity (FVC) <50% predicted. Time to progression was analyzed using the Kaplan‐Meier method.ResultsOf the 167 patients included in the study, 81 (49%) were female, with a mean ± SD age of 67 ± 10 years at diagnosis of ILD. Median follow‐up time from diagnosis of ILD was 3.3 years (range 0.01–14.8). One‐third of the patients required supplemental oxygen, 40% developed DLco <40% predicted, and 22% developed FVC <50% predicted within 5 years after ILD diagnosis. Usual interstitial pneumonia (UIP) versus nonspecific interstitial pneumonia (NSIP) was a risk factor for DLco progression (hazard ratio 3.29 [95% confidence interval 1.28–8.41]). Lower DLco and FVC at baseline increased the risk for progression to DLco <40% predicted and FVC <50% predicted, and higher rates of change in the first 6 months also increased the risk of progression.ConclusionProgressive loss of pulmonary function is common in RA‐associated ILD and is worse in patients with UIP than in those with NSIP. Predictors of progression in patients with RA‐associated ILD may aid clinicians in identifying patients at highest risk for progression of ILD.
Replicating Single-Cycle Adenovirus Vectors Generate Amplified Influenza Vaccine Responses
Crosby, Catherine M. , Matchett, William E. , Anguiano-Zarate, Stephanie S., Parks, Christopher A. , Pease, Larry R. , Barry, Michael A. , Weaver, Eric A. , Webby, Richard J. , Weaver, Eric A , Barry, Michael A

Mayo Clinic

Journal of Virology | November 3, 2016 | Volume: 91 | Issue: 2 | Pages: No page available

10.1128/jvi.00720-16 | PMID 27807231 Get It

ABSTRACT Head-to-head comparisons of conventional influenza vaccines with adenovirus (Ad) gene-based vaccines demonstrated that these viral vectors can mediate more potent protection against influenza virus infection in animal models. In most cases, Ad vaccines are engineered to be replication-defective (RD-Ad) vectors. In contrast, replication-competent Ad (RC-Ad) vaccines are markedly more potent but risk causing adenovirus diseases in vaccine recipients and health care workers. To harness antigen gene replication but avoid production of infectious virions, we developed “single-cycle” adenovirus (SC-Ad) vectors. Previous work demonstrated that SC-Ads amplify transgene expression 100-fold and produce markedly stronger and more persistent immune responses than RD-Ad vectors in Syrian hamsters and rhesus macaques. To test them as potential vaccines, we engineered RD and SC versions of adenovirus serotype 6 (Ad6) to express the hemagglutinin (HA) gene from influenza A/PR/8/34 virus. We show here that it takes approximately 33 times less SC-Ad6 than RD-Ad6 to produce equal amounts of HA antigen in vitro . SC-Ad produced markedly higher HA binding and hemagglutination inhibition (HAI) titers than RD-Ad in Syrian hamsters. SC-Ad-vaccinated cotton rats had markedly lower influenza titers than RD-Ad-vaccinated animals after challenge with influenza A/PR/8/34 virus. These data suggest that SC-Ads may be more potent vaccine platforms than conventional RD-Ad vectors and may have utility as “needle-free” mucosal vaccines. IMPORTANCE Most adenovirus vaccines that are being tested are replication-defective adenoviruses (RD-Ads). This work describes testing newer single-cycle adenovirus (SC-Ad) vectors that replicate transgenes to amplify protein production and immune responses. We show that SC-Ads generate markedly more influenza virus hemagglutinin protein and require substantially less vector to generate the same immune responses as RD-Ad vectors. SC-Ads therefore hold promise to be more potent vectors and vaccines than current RD-Ad vectors.
A phase IIa study of afuresertib, an oral pan‐AKT inhibitor, in patients with Langerhans cell histiocytosis
Arceci, R.J., Allen, Carl E. , Jacobsen, Eric D. , Whitlock, James A. , Vassallo, Robert , Morris, Shannon R., Portnoy, Alison, Reedy, Beth Ann, Smith, Deborah A. , Noble, Robert, Murnane, Amy A., Cornfeld, Mark, Heaney, Mark , McClain, Kenneth L. , Vaiselbuh, Sarah R., Dunkel, Ira J. , Rodríguez‐Galindo, Carlos , Vassallo, Robert , McClain, Kenneth L , Allen, Carl E

Mayo Clinic

Pediatric Blood & Cancer | November 2, 2016 | Volume: 64 | Issue: 5 | Pages: No page available

10.1002/pbc.26325 | PMID 27804235 Get It

AbstractBackgroundLangerhans cell histiocytosis (LCH) is a clonal neoplasm characterized by widely varied clinical presentations, including multisystem involvement and systemic inflammatory symptoms. The AKT pathway is relevant to survival and proliferation of dendritic cells, and is also often upregulated in hematopoietic malignancies. A clinical response in an adult patient with LCH participating in the first‐in‐human trial of afuresertib prompted this prospective trial.ProcedureThe population in the current study included treatment‐naïve (n = 7) and recurrent/refractory patients with LCH (n = 10), who received oral afuresertib (125 mg). The majority of patients were treated for > 24 weeks, with four patients receiving treatment for > 48 weeks.ResultsPharmacokinetic analysis showed similar exposures in previously reported patients with other hematologic malignancies. Primary drug‐related toxicities included Grade 1/2 nausea, diarrhea, dyspepsia, and vomiting. Grade 3 toxicities included fatigue, diarrhea, and pain (one of each). Another severe adverse event involved soft tissue necrosis. The overall response rate in evaluable subjects was 33% in treatment‐naïve patients and 28% in patients with recurrent/refractory disease, which did not meet the predefined Bayesian criteria for efficacy.ConclusionAfuresertib has clinical activity in some patients with newly diagnosed and advanced LCH.
Prospective associations of plasma phospholipids and mild cognitive impairment/dementia among African Americans in the ARIC Neurocognitive Study
Li, Danni , Misialek, Jeffrey R. , Boerwinkle, Eric , Sharrett, A. Richey, Wruck, Lisa , Alonso, Álvaro , Gottesman, Rebecca F. , Mosley, Thomas H. , Coresh, Josef , Knopman, David S. , Alonso, Alvaro , Wruck, Lisa M

Mayo Clinic

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | November 1, 2016 | Volume: 6 | Issue: 1 | Pages: 1-10

10.1016/j.dadm.2016.09.003 | PMID 28054030 Get It

AbstractIntroductionThe objective of this study was to investigate whether 10 phospholipids/metabolites previously identified as prospectively predictive of mild cognitive impairment (MCI) or dementia in whites would also be predictive in a mostly African‐American cohort.MethodsWe repeatedly measured 188 phospholipids/metabolites in plasma samples of 221 participants of the Atherosclerosis Risk in Communities study, 97% African American, who were followed between 2004–2006 and 2011–2013.ResultsAfter a mean follow‐up of 7.3 years, 77 were classified as having MCI and 18 as having dementia. Our study failed to replicate previous findings in this mostly African American cohort, in that the 10 phospholipids/metabolites only achieved a C statistic/AUC of 0.609 in predicting development of MCI or dementia (compared to 0.96) and 0.607 in distinguishing normal from MCI or dementia at the follow‐up visit.ConclusionA panel of 10 phospholipids/metabolites previously associated with incident dementia was not predictive of MCI or dementia in an independent cohort.
Safety Studies for Use of Adipose Tissue-Derived Mesenchymal Stromal/Stem Cells in a Rabbit Model for Osteoarthritis to Support a Phase I Clinical Trial
Riester, Scott M. , Denbeigh, Janet M. , Yang, Lin , Jones, Dakota L. , Mooij, Tristan de, Lewallen, Eric A. , Nie, Hai , Paradise, Christopher R. , Radel, Darcie J., Dudakovic, Amel , Camilleri, Emily T. , Qu, Wenchun , Krych, Aaron J. , Frick, Matthew A., Im, Hee‐Jeong , Dietz, Allan B. , Smith, Jay , Wijnen, André J. van , Camilleri, Emily , Lin, Yang , de Mooij, Tristan, Larson, Dirk R. , van Wijnen, Andre J, van Wijnen, Andre J , Krych, Aaron J , Dietz, Allan B , van Wijnen, Andre J , Camilleri, Emily

Mayo Clinic

Stem Cells Translational Medicine | October 27, 2016 | Volume: 6 | Issue: 3 | Pages: 910-922

10.5966/sctm.2016-0097 | PMID 28297568 Get It

AbstractAdipose-derived mesenchymal stem cells (AMSCs) offer potential as a therapeutic option for clinical applications in musculoskeletal regenerative medicine because of their immunomodulatory functions and capacity for trilineage differentiation. In preparation for a phase I clinical trial using AMSCs to treat patients with osteoarthritis, we carried out preclinical studies to assess the safety of human AMSCs within the intra-articular joint space. Culture-expanded human AMSCs grown in human platelet-lysate were delivered via intra-articular injections into normal healthy rabbit knees and knees at risk for the development of osteoarthritis after bilateral medial anterior hemimeniscectomy. Treatment outcomes and safety were evaluated by assessing the general health, function, and behavior of the animals. Joint tissues were analyzed by x-ray, magnetic resonance imaging, and histopathology. Intra-articular AMSC therapy was well tolerated in this study. We did not observe adverse systemic reactions, nor did we find evidence of damage to intra-articular joint tissues. Thus, the data generated in this study show a favorable safety profile for AMSCs within the joint space in support of a phase I clinical trial evaluating the clinical utility of AMSCs to treat osteoarthritis.
Safety of intrathecal autologous adipose-derived mesenchymal stromal cells in patients with ALS
Staff, Nathan P. , Madigan, Nicolas N. , Jentoft, Mark E. , Sorenson, Eric J. , Butler, Greg W., Gastineau, Dennis A., Dietz, Allan B. , Windebank, Anthony J. , Jentoft, Mark, Butler, Greg, Gastineau, Dennis, Dietz, Allan, Morris, Jonathan M. , Gastineau, Dennis A. , Staff, Nathan P , Dietz, Allan B

Mayo Clinic

Neurology | October 26, 2016 | Volume: 87 | Issue: 21 | Pages: 2230-2234

10.1212/wnl.0000000000003359 | PMID 27784774 Get It